Is Innate Pharma S.A. (IPHA) a Buy, Sell, or Hold?
NASDAQ : IPHA
Innate Pharma S.A.
$1.75 USD
-$0.03 (-1.41%)
- Volume
- 10.42K
- Average Volume
- 68.57K
- Market Capitalization
- $164.33M
- P/E Ratio
- -2.74
- Dividend Yield
- 0.00%
- Price Target
- $3.50
- Year High
- $2.63
- Year Low
- $1.17
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.27
| Source | Headline |
|---|---|
|
Outcome of Innate Pharma's 2026 Annual General Meeting
MARSEILLE, France--(BUSINESS WIRE)--Outcome of Innate Pharma's 2026 Annual General Meeting. businesswire.com - 2026-05-22 01:00:00 |
|
B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic
/PRNewswire/ -- USA News Group News Commentary - For more than two decades, B7-H3 sat on the shortlist of theoretically perfect cancer drug targets that nobody prnewswire.com - 2026-05-18 14:22:00 |
|
Innate Pharma Q1 Earnings Call Highlights
Innate Pharma NASDAQ: IPHA said its first-quarter 2026 business update centered on three priority clinical assets: lacutamab in cutaneous T-cell lymphoma, the Nectin-4 antibody-drug conjugate IPH4502 in advanced solid tumors, and the AstraZeneca-partnered monalizumab program in non-small cell lung cancer. marketbeat.com - 2026-05-13 12:07:58 |
|
Innate Pharma Reports First Quarter 2026 Business Update and Financial Results
MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its business update and consolidated financial results for the quarter ending March 31, 2026. “We have continued to make solid progress across our priority clinical assets during the first quarter. We are approaching completion of enrollment in the Phase 1 dose escalation and backfill cohorts for IPH4502. In parallel, we have advanced the negotiati. businesswire.com - 2026-05-13 01:00:00 |
|
Number of Shares and Voting Rights of Innate Pharma as of April 16, 2026
MARSEILLE, France--(BUSINESS WIRE)--Number of shares and voting rights of Innate Pharma as of April 16, 2026. businesswire.com - 2026-05-12 01:00:00 |
|
Innate Pharma Announces Conference Call and Webcast for Q1 2026 Business Update
MARSEILLE, France--(BUSINESS WIRE)---- $Innate #Biotech--Innate Pharma announces conference call and webcast for Q1 2026 Business Update. businesswire.com - 2026-05-06 01:00:00 |
|
Innate Pharma to Participate in the D. Boral Capital Global Conference
MARSEILLE, France--(BUSINESS WIRE)-- #Biotech--Innate Pharma to participate in the D. Boral Capital Global Conference. businesswire.com - 2026-04-23 01:00:00 |
